BioSpace News Archive

Noxopharm , a clinical-stage Australian oncology drug development company, has announced the details of the radiographic review of its DARRT-1 clinical study and is pleased to report a 27% incidence of abscopal response in soft tissue lesions using a combination of Veyonda® and low-dose radiotherapy. An abscopal response, a highly prized clinical response, involves radiation directed at a single tumor which triggers resulting

Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the pricing of an underwritten public offering of 9,100,000 shares of its common stock at a price to the public of $13.75 per share. The gross proceeds to Kura from the offering, before deducting underwriting discounts and commissions and other offering expenses payable b

Alpha Pro Tech, Ltd., a leading manufacturer of products designed to protect people, products and environments, including disposable protective apparel and building products, announced financial results for the three month period ended March 31, 2020 and provided an update on personal protective equipment orders resulting from the COVID-19 pandemic.

ARTMS Products Inc . (ARTMS), a global leader in the development of novel technologies enabling the production of the world’s highest demand diagnostic imaging isotopes, and Telix Pharmaceuticals Limited (Telix), a clinical-stage biopharmaceutical company developing diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) announced today they have entered into a development

Allovate Therapeutics , a New York-based biotechnology company, announced today that it is making its allergy immunotherapy delivery platform available without charge to allergy professionals facing difficulties bringing their patients into the office for injections. Allovate was founded in 2012 with the goal of improving and advancing the administration of allergy immunotherapy for patients of all ages. Allovate’s lead product, Allerdent ® , is

Otezla Treatment Resulted in Significant Improvements in Measures of Mild-to-Moderate Psoriasis Compared With Placebo Data Will be Submitted to the U.S. Food and Drug Administration (FDA) for Inclusion in Otezla Prescribing Information

BERG, a clinical-stage biotech company that uses artificial intelligence (AI) to research diseases and develop innovative treatments, today announced a new collaboration with Boehringer Ingelheim around understanding the multifaceted nature of the spectrum of inflammatory diseases and seeks to unravel the associated biological drivers.

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission critical products and services to customers in the life sciences and advanced technologies & applied materials industries, will participate in the Bank of America Securities 2020 Healthcare Conference, taking place virtually on Tuesday, May 12. Avantor’s presentation is sc

The Neuromuscular Disease Foundation (NDF) will launch its annual Symposium on GNE Myopathy Speaker Series on Friday, May 8th, albeit in a much different format than in previous years.

Customizable certification to restore public confidence; trust in protective measures launches nationwide